Kala Pharmaceuticals Inc. appointed Gregory Perry to its board of directors.
Perry is the former chief financial and administrative officer of Novelion Therapeutics Inc.
"Greg brings a wealth of business, strategic and financial expertise gained during his accomplished career in the biotech industry. We look forward to benefitting from his guidance as the company matures and we continue to advance toward commercialization," Kala Chairman and CEO Mark Iwicki said in a statement.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle technology, with an initial focus on the treatment of eye diseases.
